SDGR — Schrodinger, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1490978 ·
Last close
$18.77
Market Cap
$1.23B
52W High
$20.48
52W Low
$13.05
ADV30
1,076,988
Next earnings
2026-11-04
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 58,889,000 32,432,000 -41,547,000 5,975,000 640,394,000 287,853,000 311,438,000
Mar 2026 58,587,000 29,547,000 -48,794,000 -60,026,000 634,187,000 260,255,000 320,639,000
Dec 2025 87,235,000 57,293,000 -17,157,000 32,511,000 726,160,000 230,517,000 362,107,000
Sep 2025 54,324,000 28,039,000 -45,947,000 -32,795,000 653,660,000 172,120,000 332,308,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-126,870,000
Investing CF
$186,083,000
Financing CF
$1,723,000
CapEx
$-3,401,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.77
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-682,857,000
Inventory
Receivables
$41,124,000
ST Investments
$125,886,000
EBIT TTM
$-153,445,000
Pretax Income TTM
$-51,931,000
Interest Exp TTM
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$259,035,008
EBITDA
$-147,579,008
Free Cash Flow
$-29,163,124
Enterprise Value
$1,168,682,880
Total Cash
$413,739,008
Total Debt
$108,003,000
Shares Out
65,641,435
Trailing EPS
$-0.73
Book Value
$4.51
ROE
-16.2%
ROA
-14.4%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 255,869,000 -166,896,000 -103,265,000 726,160,000 362,107,000 13,899,000
Dec 2024 207,539,000 -209,296,000 -187,123,000 823,226,000 401,781,000 -157,368,000
Dec 2023 216,666,000 -177,448,000 40,720,000 802,955,000 254,397,000 -136,733,000
Dec 2022 180,955,000 -146,817,000 -149,186,000 688,587,000 240,682,000 -119,683,000

TTM Snapshot

Revenues TTM
$144,689,000
NetIncome TTM
$-175,020,000
OpCashFlow TTM
$0
Assets (Latest)
$823,226,000
Forward EPS
$-1.35

Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $20.00 · spot: $18.77 · call volume: 442 · put volume: 182
Expected Move to 2026-09-18: ±$2.38 (12.68%) — implied range $16.39$21.15 · ATM straddle on $20.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MRVI MARAVAI LIFESCIENCES HOLDINGS, INC. $1.26B $8.43
EVOTF Evotec SE $1.19B $6.69
CRVS Corvus Pharmaceuticals, Inc. $1.19B $14.09
SPTX Seaport Therapeutics, Inc. $1.29B $24.08
MLTX MoonLake Immunotherapeutics $1.31B $15.37

News headlines (Yahoo Finance, 1h cache)

Schrodinger Q2 Earnings Call Highlights
2026-08-06 05:03 · Yahoo
Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates
2026-08-06 00:35 · Yahoo
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
2026-08-17 13:56 · Yahoo
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-08-14 12:30 · Yahoo
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
2026-08-11 18:00 · Yahoo
Schrödinger (SDGR) Is Up 8.5% After AI Co‑Scientist Deal With BMS And Q2 Profitability Shift – Has The Bull Case Changed?
2026-08-06 06:09 · Yahoo
Schrodinger Inc (SDGR) (Q2 2026) Earnings Call Highlights: ACV Surges 27% on Bunsen Launch and ...
2026-08-06 05:08 · Yahoo
Schrödinger Reports Second Quarter 2026 Financial Results
2026-08-05 20:05 · Yahoo
Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery
2026-08-05 12:30 · Yahoo
Schrödinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery
2026-07-27 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.